Results 151 to 160 of about 137,002 (346)

Glucagon receptor family in GtoPdb v.2025.3 [PDF]

The glucagon family of receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on the Glucagon receptor family [170]) are activated by the endogenous peptide (27-44 aa) hormones glucagon, glucagon-like peptide 1, glucagon-like peptide 2, glucose ...
Bataille, Dominique, Chan, Susan L., Delagrange, Philippe, Drucker, Daniel J., Göke, Burkhard, Hills, Rebecca, Mayo, Kelly E., Miller, Laurence J., Salvatori, Roberto, Thorens, Bernard   +9 more
core   +2 more sources

Bioengineered Isoflavone–Probiotic Functional Foods for Sustainable Modulation of Metabolic and Reproductive Health in PCOS

Food Bioengineering, EarlyView.
Synergistic isoflavone‐probiotic action modulated metabolic, microbial and ovarian pathway ABSTRACT Polycystic ovary syndrome (PCOS) is a prevalent metabolic–endocrine disorder characterized by insulin resistance, hyperandrogenism, chronic inflammation, oxidative stress, and ovarian dysfunction, with growing evidence implicating gut microbiota ...
Jeyavelkumaran Renukadevi, Panneerselvam Sneha, Dhanapal Saravanan Mridula, Keerthivasan Nimithasree, Valliappan Sanjay   +4 more
wiley   +1 more source

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

Diabetes Care, 2011
Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. Clinical data have revealed that these therapies improve glycemic control while reducing body weight (GLP-1 receptor
openaire   +1 more source

Current Advancements of Probiotic Foods and Their Role in Sustainable Food Security

Food Bioengineering, EarlyView.
ABSTRACT Probiotic foods have evolved from traditional fermented products to scientifically validated functional foods, defined by the FAO and WHO as live microorganism that confer a health benefit on the host when administered in adequate amounts, with effects being strain, does and end point specific.
Ashenafi Teklay Yaekob, Gebremedhin Gebreslassie, Etsay Mesele, Tesfakiros Semere   +3 more
wiley   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

Clinical Hypertension
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension.
Hae Young Lee, Seung-Hyun Ko, Sungjoon Park, Kyuho Kim, Song-Yi Kim, In-Jeong Cho, Eun Joo Cho, Hyeon Chang Kim, Jae-Hyeong Park, Sung Kee Ryu, Min Kyong Moon, Sang-Hyun Ihm, the Korean Society of Hypertension   +12 more
doaj   +1 more source

Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction

Quality in Sport
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2.
Arkadiusz Staroń, Patrycja Karkos, Katarzyna Kuśmierczyk, Bartłomiej Gastoł, Karolina Mikołap, Marta Kras, Marta Jurga   +6 more
doaj   +1 more source

Metabolic Signatures and Diagnostic Prediction Models for Coronary Artery Disease and Type 2 Diabetes Mellitus: Insights From an Exploratory Study

iNew Medicine, EarlyView.
Metabolomic & lipidomic analysis reveals metabolic overlap between CAD & T2DM, highlighting 7 key metabolites as potential biomarkers. A predictive model based on these achieves high accuracy, potentially advancing precision medicine & metabolic insights.
Zhihua Wang, Meiming Su, Ying Li, Yapei Li, Shuo Chen, Ting Peng, Hans Strijdom, Jiangang Wang, Jianping Weng, Suowen Xu   +9 more
wiley   +1 more source

Gut microbiome‐derived metabolites show promise in cancer research and therapy

Interdisciplinary Medicine, EarlyView.
The metabolites produced by the gut microbiome, which are subject to regulation by multiple factors, play a pivotal role in the progression of various types of cancer. These metabolites not only function as potential biomarkers for the early detection and monitoring of tumor development, but also actively participate in cancer therapeutic processes ...
Kangjie Yang, Yifan Wang, Daolin Tang, Peilong Li, Lutao Du   +4 more
wiley   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source